Last $4.78 USD
Change Today -0.57 / -10.75%
Volume 5.8M
CERS On Other Exchanges
Symbol
Exchange
CERS is not on other exchanges.
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

cerus corp (CERS) Snapshot

Open
$5.16
Previous Close
$5.35
Day High
$5.18
Day Low
$4.54
52 Week High
01/5/15 - $7.03
52 Week Low
07/28/14 - $3.48
Market Cap
429.4M
Average Volume 10 Days
914.7K
EPS TTM
$-0.50
Shares Outstanding
89.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CERUS CORP (CERS)

cerus corp (CERS) Related Bloomberg News

View More Bloomberg News

cerus corp (CERS) Related Businessweek News

No Related Businessweek News Found

cerus corp (CERS) Details

Cerus Corporation, together with its subsidiary, Cerus Europe B.V., operates as a biomedical products company in Europe, the Commonwealth of Independent States, and the Middle East. The company develops and commercializes the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication and designed to target and inactivate blood-borne pathogens, including viruses, bacteria, and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company’s INTERCEPT Blood System for platelets is designed to inactivate blood-borne pathogens in platelets donated for transfusion; INTERCEPT Blood System for plasma is designed to inactivate blood-borne pathogens in plasma donated for transfusion; and INTERCEPT Blood System for red blood cells is designed to inactivate blood-borne pathogens in red blood cells donated for transfusion. Cerus Corporation markets its platelet and plasma systems through its direct sales force and distributors. The company has collaboration agreements with Baxter International, Inc. for the development and commercialization of the INTERCEPT Blood System. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

cerus corp (CERS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $495.8K
Co-Founder, Chief Medical Officer, Chief Scie...
Total Annual Compensation: $398.2K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $277.0K
President of Cerus Europe and EEMEA
Total Annual Compensation: $304.4K
Senior Vice President of Regulatory Affairs, ...
Total Annual Compensation: $315.4K
Compensation as of Fiscal Year 2013.

cerus corp (CERS) Key Developments

Cerus Corporation Announces Unaudited Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for the First Quarter and Full Year of 2015

Cerus Corporation announced unaudited consolidated financial results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported revenue of $9.674 million against $9.232 million a year ago. Loss from operations was $12.775 million against $7.806 million a year ago. Loss from operations before income taxes was $19.888 million against $5.807 million a year ago. Net loss was $19.993 million or $0.25 per diluted share against $5.860 million or $0.10 per diluted share a year ago. Increased operating expenses realized during the quarter and year ended December 31, 2014, relative to the same periods in 2013 were the primary drivers for the higher operating losses. Net loss was impacted by the mark-to-market adjustments of the Company's outstanding warrants to fair value. For the year, the company reported revenue of $36.503 million against $39.657 million a year ago. Loss from operations was $44.349 million against $28.299 million a year ago. Loss from operations before income taxes was $38.371 million against $43.119 million a year ago. Net loss was $38.566 million or $0.60 per diluted share against $43.337 million or $0.64 per diluted share a year ago. The lower revenue for 2014 relative to 2013 was a result of transitions to a direct sales force during 2014 in certain historical distributor geographies. Net loss was impacted by the mark-to-market adjustments of the Company's outstanding warrants to fair value. For the year, operating results were impacted by noncash gains of $7.7 million. For the first quarter of 2015 revenue is expected to decrease by at least $2 million from fourth quarter of 2014 based primarily on weakness in the Russian market, and to a lesser extent, on continued weakness in the Euro. The company anticipates cash used for operating activities will increase in 2015 to an average of $12 million to $13 million a quarter, up from the approximately $10 million a quarter the company experienced in 2014.

Cerus Corporation to Report Q4, 2014 Results on Feb 26, 2015

Cerus Corporation announced that they will report Q4, 2014 results After-Market on Feb 26, 2015

Cerus Corporation, Q4 2014 Earnings Call, Feb 26, 2015

Cerus Corporation, Q4 2014 Earnings Call, Feb 26, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CERS:US $4.78 USD -0.57

CERS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Antares Pharma Inc $2.61 USD -0.04
AtriCure Inc $17.68 USD -0.25
Pluristem Therapeutics Inc $3.04 USD -0.01
STAAR Surgical Co $6.86 USD -1.07
SurModics Inc $24.05 USD +0.32
View Industry Companies
 

Industry Analysis

CERS

Industry Average

Valuation CERS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.2x
Price/Book 8.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CERUS CORP, please visit www.cerus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.